Anlon Healthcare IPO: A Strong Start with Full Subscription on Day 1
Anlon Healthcare Ltd., a leading manufacturer of APIs, pharmaceutical intermediates, and nutraceuticals, launched its initial public offering (IPO) on August 26, 2024. The IPO, which aims to raise Rs 121.03 crore, was fully subscribed on the first day of its opening, with strong demand from retail investors.
The mainboard IPO, which comprises entirely of a fresh issue of 1.33 crore shares, saw a subscription of 1.69 times as of 5 p.m. on Tuesday. The company has set aside 75% of the net issue for Qualified Institutional Buyers (QIBs), 15% for Non-Institutional Investors (NIIs), and 10% for retail investors.
Retail Investors Lead the Bidding
Retail investors have shown strong interest in the Anlon Healthcare IPO, with the retail category being subscribed 8.99 times. This indicates a high level of confidence among retail investors in the company’s growth prospects and the pharmaceutical sector as a whole.
For retail investors, the minimum application size is 1 lot of 164 shares, amounting to an investment of at least Rs 14,924. Small High Net-worth Individuals (S-HNIs) can apply for a minimum of 14 lots (2,296 shares), worth Rs 2,08,936, while Big High Net-worth Individuals (B-HNIs) can apply for at least 68 lots (11,152 shares), amounting to a minimum investment of Rs 10,14,832.
Grey Market Premium Indicates Listing Gain
The grey market premium of Anlon Healthcare was at Rs 5 as of 5:29 p.m. on InvestorGain, indicating a listing gain of 5.49% based on the implied listing price of Rs 96. This suggests that investors are expecting a strong listing for the company’s shares.
Interactive Financial Services Ltd. is the lead manager for the IPO, while Kfin Technologies Ltd. is the registrar. The mainboard IPO will remain open for subscription from August 26 to August 29, and the company is expected to finalize the IPO share allotment on September 1.
Company Profile and Business Overview
Anlon Healthcare Ltd. was founded in 2013 and is based in Rajkot, Gujarat. The company began its manufacturing operations in 2017 and is primarily engaged in the production of APIs, pharmaceutical intermediates, and nutraceuticals.
The company’s products are used in various therapeutic segments, including antibiotics, antivirals, and cardiovascular drugs. Anlon Healthcare has a strong research and development team, which focuses on developing new products and improving existing ones.
Investment Rationale and Growth Prospects
The Anlon Healthcare IPO offers an opportunity for investors to participate in the growth of the pharmaceutical sector, which is expected to continue growing in the coming years. The company’s strong product portfolio, research and development capabilities, and experienced management team are expected to drive growth and returns for investors.
However, investors should also consider the risks associated with the IPO, including the competitive nature of the pharmaceutical sector, regulatory risks, and the company’s dependence on a few key products.
Conclusion
The Anlon Healthcare IPO has got off to a strong start, with full subscription on the first day of its opening. Retail investors have shown strong interest in the IPO, and the grey market premium indicates a listing gain. While there are risks associated with the IPO, the company’s strong product portfolio and growth prospects make it an attractive investment opportunity for those looking to invest in the pharmaceutical sector.
As the IPO remains open for subscription, investors should carefully evaluate the company’s financials, growth prospects, and risks before making an investment decision. It is also essential to consult with a financial advisor or broker to get a better understanding of the IPO and its potential returns.